Home
/
Industries
/
Healthcare & life sciences
Healthcare & life sciences

Your data outlives your cryptography by decades.
Most sectors cannot say that.

Patient records, clinical trial data and formulation IP stay valuable for thirty years or more. The cryptography protecting them has a published expiry date. That gap is what makes harvest-now-decrypt-later concrete here rather than theoretical.

Plan a pilot
See the timeline
The lifetime gap

Retention obligations versus cryptographic viability

Put the two timelines side by side and the prioritization argument makes itself.

Why this sector is different

In most industries the harvest-now-decrypt-later argument requires a hypothetical. Here it does not. Data encrypted today under RSA-2048 will still be commercially and clinically sensitive when the standards that permit RSA-2048 have expired. Data classification and retention become the primary input to migration sequencing.

What makes change expensive here

Validated systems resist cryptographic change by design

GxP and validated environments are engineered for stability. That is a feature for patient safety and a genuine obstacle for crypto-agility.

Revalidation cost

Changing a cryptographic library inside a validated system can trigger requalification. The cost is not the code change, it is the documentation and testing burden that follows.

Long-lived signed records

Electronic records and signatures under 21 CFR Part 11 must stay verifiable long after they were created. What happens to signature validity when the signing algorithm is disallowed is a question few programmes have answered.

Change control windows

Manufacturing and clinical systems have narrow, scheduled change windows. Cryptographic migration competes with every other change on the same calendar.

The device estate

Connected medical devices are a cryptographic estate you did not write

Infusion pumps, imaging systems, patient monitors and lab analyzers carry embedded cryptography, ship on vendor firmware cycles, and often cannot be patched on your schedule. Discovery here is a vendor-management problem as much as a technical one.

Regulatory context

HIPAA, Part 11, the FDA and MDR: where the proof requests come from

Framework
Relevance to cryptography
Evidence Qinsight supports
HIPAA Security Rule
Encryption as an addressable safeguard for protected health information at rest and in transit
Where encryption is and is not applied, with deployment context
21 CFR Part 11
Electronic records and electronic signatures in FDA-regulated systems
Signature algorithm inventory and validity horizon
FDA premarket cybersecurity
Cybersecurity information expected in device submissions, including a software bill of materials
CBOM generation alongside SBOM for submitted devices
EU MDR / IVDR
Security requirements for medical devices placed on the EU market
Cryptographic posture per device family
HITRUST CSF
Control framework widely used for third-party assurance in healthcare
Inventory and coverage evidence for cryptographic controls

Start where the retention horizon is longest

Pick one data class with a decades-long obligation and map the cryptography protecting it end to end.